Company: PRME
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0001628280-25-008884
Chunk: 255

Company: Prime Medicine, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 16
Chunk 255
---
$(2.18)Weighted-average common shares outstanding, basic and diluted118,600,381 90,969,327 Comprehensive loss:Net loss$(195,882)$(198,133)Change in unrealized loss on investments, net of tax16 369 Comprehensive loss$(195,866)$(197,764)

__________________

(1)Includes related party amounts of $— million and $0.6 million for the years ended December 31, 2024 and 2023, respectively.

The accompanying notes are an integral part of these consolidated financial statements. 

F-4

PRIME MEDICINE, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive LossAccumulated DeficitTotal Stockholders' Equity(in thousands, except share amounts)SharesAmountBalances at December 31, 202297,209,213 $2 $609,849 $(384)$(293,197)$316,270 Issuance of common stock upon exercise of stock options167,908 — 655 — — 655 Stock-based compensation expense— — 13,910 — — 13,910 Change in unrealized loss on investments, net of tax— — — 369 — 369 Net loss— — — — (198,133)(198,133)Balances at December 31, 202397,377,121 $2 $624,414 $(15)$(491,330)$133,071 Issuance of common stock from public offering, net of issuance costs of $8.9 million22,560,001 — 132,055 — — 132,055 Issuance of pre-funded warrants, net of issuance costs of $1.2 million— — 18,800 — — 18,800 Issuance of common stock under the Securities Purchase Agreement to BMS — related party (Note 9)11,006,163 — 38,081 — — 38,081 Issuances of common stock under the employee stock purchase plan189,509 — 837 — — 837 Issuances of common stock upon exercise of stock options28,048 — 103 — — 103 Stock-based compensation expense